Related Experiment Video
Updated: Jun 6, 2026
06:07
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Pediatric antiretroviral therapy
Adriana Cadilla1, Nadia Qureshi, Daniel C Johnson
1University of Chicago, Pritzker School of Medicine, 5841 S. Maryland Avenue, MC6082, Chicago, IL 60637, USA.
Expert Review of Anti-Infective Therapy
|December 8, 2010
Summary
Antiretroviral therapy options for children with HIV have expanded. This overview covers new pediatric HIV treatment guidelines, drugs, and management strategies for children and adolescents.
Area of Science:
- Pediatric Infectious Diseases
- HIV/AIDS Research
- Pharmacology
Background:
- Perinatal HIV transmission is declining in developed nations but remains a primary source of pediatric HIV globally.
- Advances in clinical trials, viral resistance testing, and new medications have broadened initial treatment choices.
- Effective antiretroviral therapy (ART) is crucial for managing pediatric HIV.
Purpose of the Study:
- To provide an overview of current antiretroviral therapy for treatment-naive children with HIV.
- To present updated pediatric HIV treatment guidelines and recent clinical trial findings.
- To detail new ART drugs, dosages, resistance testing, and monitoring for pediatric populations.
Main Methods:
- Review of recent clinical trial data.
- Analysis of updated National Institutes of Health (NIH) guidelines.
- Compilation of information on newly approved pediatric antiretroviral drugs.
- Summary of drug resistance testing and monitoring recommendations.
Main Results:
- Significant advancements in ART have increased treatment options for children.
- New drugs and updated guidelines offer improved management strategies.
- Comprehensive information on pediatric ART, including adherence and contraception, is now available.
Conclusions:
- Current ART regimens offer effective options for children and adolescents with HIV.
- Adherence, disclosure, and contraception are critical considerations in pediatric HIV management.
- Ongoing research and updated guidelines are essential for optimizing pediatric HIV care.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...